Business Description
Organon & Co
NAICS : 325412
SIC : 2834
ISIN : US68622V1061
Share Class Description:
OGN: Ordinary SharesDescription
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | 0.01 | |||||
| Debt-to-Equity | 60.11 | |||||
| Debt-to-EBITDA | 6.05 | |||||
| Interest Coverage | 2.56 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.33 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.8 | |||||
| 3-Year EBITDA Growth Rate | -21.2 | |||||
| 3-Year EPS without NRI Growth Rate | -23.5 | |||||
| 3-Year FCF Growth Rate | -35 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 3.33 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 1.07 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.89 | |||||
| 9-Day RSI | 53.61 | |||||
| 14-Day RSI | 43.75 | |||||
| 6-1 Month Momentum % | 2.79 | |||||
| 12-1 Month Momentum % | 29.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.64 | |||||
| Quick Ratio | 1.17 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 173.61 | |||||
| Days Sales Outstanding | 94.65 | |||||
| Days Payable | 158.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.99 | |||||
| Dividend Payout Ratio | 0.32 | |||||
| Forward Dividend Yield % | 5.99 | |||||
| 5-Year Yield-on-Cost % | 5.99 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 7.73 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.59 | |||||
| Operating Margin % | 21.18 | |||||
| Net Margin % | 15.76 | |||||
| FCF Margin % | 12.4 | |||||
| ROE % | Neg. Equity | |||||
| ROA % | 8.61 | |||||
| ROIC % | 24.24 | |||||
| 3-Year ROIIC % | 72.83 | |||||
| ROC (Joel Greenblatt) % | 52.74 | |||||
| ROCE % | 13.11 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 4.61 | |||||
| Forward PE Ratio | 4.17 | |||||
| PE Ratio without NRI | 5.14 | |||||
| Price-to-Owner-Earnings | 8.39 | |||||
| PS Ratio | 0.73 | |||||
| PB Ratio | 32.08 | |||||
| Price-to-Free-Cash-Flow | 5.86 | |||||
| Price-to-Operating-Cash-Flow | 4.33 | |||||
| EV-to-EBIT | 10.65 | |||||
| EV-to-EBITDA | 8.78 | |||||
| EV-to-Revenue | 1.98 | |||||
| EV-to-FCF | 15.97 | |||||
| Earnings Yield (Greenblatt) % | 9.39 | |||||
| FCF Yield % | 17.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:OGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Organon & Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6,346 | ||
| EPS (TTM) ($) | 3.89 | ||
| Beta | 0.83 | ||
| Volatility % | 49.36 | ||
| 14-Day RSI | 43.75 | ||
| 14-Day ATR ($) | 0.411061 | ||
| 20-Day SMA ($) | 17.787 | ||
| 12-1 Month Momentum % | 29.34 | ||
| 52-Week Range ($) | 10.835 - 23.1 | ||
| Shares Outstanding (Mil) | 257.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Organon & Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Organon & Co Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Organon & Co Frequently Asked Questions
What is Organon & Co(OGN)'s stock price today?
The current price of OGN is $18.78. The 52 week high of OGN is $23.10 and 52 week low is $10.84.
When is next earnings date of Organon & Co(OGN)?
The next earnings date of Organon & Co(OGN) is 2024-10-31.
Does Organon & Co(OGN) pay dividends? If so, how much?
The Dividend Yield %  of Organon & Co(OGN) is 5.99% (As of Today), Highest Dividend Payout Ratio of Organon & Co(OGN) was 0.32. The lowest was 0.1. And the median was 0.27. The  Forward Dividend Yield % of Organon & Co(OGN) is 5.99%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers